Lintlha tse Ncha ho Bakuli ba Khutletseng / Refractory Multiple Myeloma

Kajeno Oncolytics Biotech® Inc. kajeno e phatlalalitse phatlalatso ea poso ea elektroniki ho Seboka sa Selemo sa Mokhatlo oa Amerika oa Patlisiso ea Kankere (AACR) se nang le lintlha tse ncha tsa kliniki tsa biomarker ho tsoa tekong e phethiloeng e tšehelitsoeng ke mofuputsi ea karolo ea 1b ea pelareorep le proteasome inhibitor bortezomib ka ho khutlela morao / ho refractory. bakuli ba bangata ba myeloma.

Thomas Heineman, MD, Ph.D., Ofisiri e ka Sehloohong ea Bongaka ea Oncolytics Biotech Inc. ho boletse Thomas Heineman, MD, Ph.D., Ofisiri e ka Sehloohong ea Bongaka ea Oncolytics Biotech ba ngolisitseng thutong ba ne ba hlōlehile liphekolo tsa pele, leha ho le joalo, phekolo e nang le pelareorep-based therapy e ile ea thibela tsoelo-pele ea mafu ka lilemo tse fetang tse tharo karolong e nyenyane ea bakuli. Ho feta moo, phuputso ena e bontša hore bokhoni ba pelareorep ba ho bokella lisele tse ngata tsa 'mele tse thibelang mofetše ka har'a tumor microenvironment (TME) li ka hlahisa liphello tse matla tsa kliniki. Sephetho sena se khahlang se na le litlamorao bakeng sa mofets'e ho feta myeloma e mengata kaha se theha lintlha tse teng tse tšehetsang bokhoni ba pelareorep ba ho ntlafatsa katleho ea mefuta e mengata ea kalafo ka bokhoni ba eona ba ho hlohlelletsa TME e thibelang ho ruruha. "

Lintlha tse tlalehiloeng nakong e fetileng tse totobalitsoeng bukeng e tsamaellanang ea poster li bonts'itse katleho ea motsoako o ithutoang mme tsa bonts'a sehlopha sa barupeluoa ba liteko ba fihletseng nako e telele ea ho phela ntle le tsoelo-pele (PFS) ea nako e fetang lilemo tse tharo (link to PR). Lintlha tsena li boetse li bontša karabelo ea kliniki e amanang le liphetoho tsa T cell clonality le ho eketseha ka mor'a phekolo ea lisele tsa 'mele tsa ho itšireletsa mafung ka hare ho TME. Litlhahlobo tse ncha tsa biomarker tse hlahang posong li bonts'a lisele tsena tsa 'mele tsa ho itšireletsa mafung tse khahlanong le mofets'e li hokahane haufi le lisele tsa mofetše tse nang le pelareorep ha li bapisoa le tse sa kang tsa etsa joalo. Ka kopanelo, liphetho tsena li bonts'a hore melemo ea bophelo bo botle e hlokometsoeng e ne e susumetsoa ke pelareorep ea ho hira lisele tsa 'mele tse thibelang mofetše ho TME.

Dr. Matt Coffey, Mopresidente le Ofisiri e ka Sehloohong ea Phethahatso ea Oncolytics Biotech Inc., o itse, "Teko ena e hlahisitse lintlha tsa bohlokoa tsa bopaki tse tiisang boemo bo botle ba polokeho ea pelareorep, ho eketsa kutloisiso ea rona ea mokhoa oa ts'ebetso, le ho ts'ehetsa ts'ebeliso. ea T cell clonality joalo ka biomarker. Lithuto tsena tsa bohlokoa li matlafatsa tšebetso ea tsamaiso e bonoang liphatlalatsong tse ling tse tšehetsang e 'ngoe le e 'ngoe ea mananeo a rona a bongaka 'me li ka sebelisoa ho potlakisa tsoelo-pele ea tsona. Ha re hatela pele, re rera ho sebelisa seo re se fumaneng ho multiple myeloma ho khanna lipuisano le bao e ka bang balekane le balekane ba nang le thahasello ho leveraging pelareorep's immunotherapeutic effects ho sebetsana le litlhoko tse sa finyelloang ho sena le lipontšo tse ling. Ka hare, re ntse re tsepamisitse maikutlo haholo lenaneong la rona la mofetše oa matsoele 'me re lebelletse ho baloa ha data ea karolo ea 2 e lebelletsoeng kotareng ea bone ea selemo. ”

Poster ea elektronike ea AACR, e nang le sehlooho se reng, Single Cell Analysis e Bontša Hore Reovirus Immune Priming e Fetola Tumor Immune Micro Environment e Multiple Myeloma, e fumaneha ho batho ba ngolisitsoeng ba tlileng kopanong ea selemo le selemo ea AACR sebakeng sa marang-rang sa kopano (Abstract #6354). Khopi ea poso e tla romelloa hape leqepheng la Liphoustara le Lingoliloeng la sebaka sa Marang-rang sa Oncolytics (LINK) kamora ho phetheloa ha kopano.